Transplantation outcomes
Transplantation outcomes . | Data . |
|---|---|
| Regimen-related organ toxicity, no. pts (%) | |
| Mucosa, no opiates | 7 (20) |
| Mucosa, opiates | 3 (9) |
| Liver* | 19 (56) |
| Renal* | 10 (29) |
| Pulmonary† | 9 (26) |
| Short-term dialysis | 1 (3) |
| Intensive care | 1 (3) |
| Early death, before d + 100, no. pts (%) | 4 (12) |
| Late death, after d + 100, no. pts (%)‡ | 2 (6) |
| Acute GvHD, no. pts (%) | |
| Grades II-IV | 14 (42) |
| Grades III-IV | 5 (15) |
| Chronic GvHD, no. pts (%) | |
| Limited | 9 (30) |
| Extensive | 4 (13) |
| Engraftment, no. pts (%) | 33 (100) |
| CC, d + 30, no. pts (%) | 31 (97) |
| CR, d + 30, no. pts (%) | 33 (100) |
| Outcome | |
| Follow-up, d, median (range) | 913 (55-1591) |
| OS at 1 y/2 y, % | 66.6/62.7 |
| EFS at 1 y/2 y, % | 53.1/53.1 |
| NRM at 1 y/2 y, % | 19.6/19.6 |
| Relapse risk 1 y/2 y, % | 27.3/27.3 |
| KPS survivors, %, median (range) | 100 (70-100) |
Transplantation outcomes . | Data . |
|---|---|
| Regimen-related organ toxicity, no. pts (%) | |
| Mucosa, no opiates | 7 (20) |
| Mucosa, opiates | 3 (9) |
| Liver* | 19 (56) |
| Renal* | 10 (29) |
| Pulmonary† | 9 (26) |
| Short-term dialysis | 1 (3) |
| Intensive care | 1 (3) |
| Early death, before d + 100, no. pts (%) | 4 (12) |
| Late death, after d + 100, no. pts (%)‡ | 2 (6) |
| Acute GvHD, no. pts (%) | |
| Grades II-IV | 14 (42) |
| Grades III-IV | 5 (15) |
| Chronic GvHD, no. pts (%) | |
| Limited | 9 (30) |
| Extensive | 4 (13) |
| Engraftment, no. pts (%) | 33 (100) |
| CC, d + 30, no. pts (%) | 31 (97) |
| CR, d + 30, no. pts (%) | 33 (100) |
| Outcome | |
| Follow-up, d, median (range) | 913 (55-1591) |
| OS at 1 y/2 y, % | 66.6/62.7 |
| EFS at 1 y/2 y, % | 53.1/53.1 |
| NRM at 1 y/2 y, % | 19.6/19.6 |
| Relapse risk 1 y/2 y, % | 27.3/27.3 |
| KPS survivors, %, median (range) | 100 (70-100) |
All patients received the FBM preparative regimen and allografted from unrelated donors. All except one patient received ATG.
pts indicates patients; s/tAML, acute myelogenous leukemia (secondary/therapy related); MDS, myelodysplastic syndrome; HCT, hematopoietic cell transplantation; CR, complete remission; REL, relapse; PB-HCT, HCT with cytokine-mobilized peripheral blood (PB) cells; BMT, bone marrow (BM) transplantation; KPS: Karnofsky performance score; d +, day after transplantation; CC, complete chimerism; OS, overall survival; EFS, event-free survival; and NRM, nonrelapse mortality.
Mild to moderate transient disturbed liver or renal function tests
intermittent oxygen support by nasal cannulas
One patient died in the context of chronic GvHD (d + 326) and one due to heart infarct (d + 230)